M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Michael D. Prados,Kathleen R. Lamborn,Susan M. Chang,Eric C. Burton,Nicholas Butowski,Mary Malec,Ami Kapadia,Jane Rabbitt,Margaretta Page,Ann Fedoroff,Dong Xie,Sean K. Kelley +11 more
TL;DR: The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted, and the recommended phase 2 dose is 200 mg/day for patients with glioblastoma multiforme who are not receiving an EIAED.
Journal ArticleDOI
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee,Regina I. Jakacki,Arzu Onar-Thomas,Shengjie Wu,Theodore Nicolaides,Tina Young Poussaint,Jason Fangusaro,Joanna J. Phillips,Arie Perry,David C. Turner,Michael D. Prados,Roger J. Packer,Ibrahim Qaddoumi,Sridharan Gururangan,Ian F. Pollack,Stewart Goldman,Lawrence A. Doyle,Clinton F. Stewart,James M. Boyett,Larry E. Kun,Maryam Fouladi +20 more
TL;DR: Selumetinib has promising antitumor activity in children with LGG and the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumet inib inChildren with progressive LGG are determined.
Journal ArticleDOI
High activity iodine-125 interstitial implant for gliomas
Cindy O. Charfen,Penny K. Sneed,William M. Wara,David A. Larson,Theodore L. Phillips,Michael D. Prados,Keith A. Weaver,Mary Malec,Pat Acord,Kathleen R. Lamborn,Sharon Lamb,Brigid Ham,Philip H. Gutin +12 more
TL;DR: This large experience demonstrates that interstitial implant is well-tolerated and prolongs survival in patients with primary and recurrent glioblastoma multiforme, as evidenced by the 3-year survival rates of 22% and 15%, respectively.
Journal Article
Differentiation of Low-Grade Oligodendrogliomas from Low-Grade Astrocytomas by Using Quantitative Blood-Volume Measurements Derived from Dynamic Susceptibility Contrast-Enhanced MR Imaging
Soonmee Cha,Tarik Tihan,Forrest W. Crawford,Nancy J. Fischbein,Susan M. Chang,Andrew W. Bollen,Sarah J. Nelson,Michael D. Prados,Mitchel S. Berger,William P. Dillon +9 more
TL;DR: Investigation of dynamic susceptibility contrast-enhanced DSC MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma suggested that tumor rCBV(max) derived from D SC MR imaging can be used to distinguish between the two low- grade gliomas.
Journal ArticleDOI
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults : Clinical article
Edward F. Chang,Justin S. Smith,Susan M. Chang,Kathleen R. Lamborn,Michael D. Prados,Nicholas Butowski,Nicholas M. Barbaro,Andrew T. Parsa,Mitchel S. Berger,Michael M. McDermott +9 more
TL;DR: A simple and reliable scoring system that can be used to preoperatively prognosticate the degree of lesion resectability, PFS, and OS in patients with LGGs is proposed.